CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference
18 Outubro 2023 - 5:30PM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of
conditionally activated, localized biologics, today announced that
the Company presented data characterizing the preclinical profile
of its EpCAM-targeting ADC, CX-2051, at the World ADC conference
taking place October 16-19, 2023, in San Diego, CA.
“CX-2051 is designed to address the unmet needs
of patients with EpCAM-expressing tumors, including colorectal
cancer, where EpCAM expression is uniformly high. EpCAM is a
broadly expressed, validated anti-cancer target that to date has
been limited in its development potential due to systemic,
on-target off-tumor dose-limiting toxicities”, said Marcia P.
Belvin, Ph.D., senior vice president and chief scientific officer
at CytomX.
Continued Dr. Belvin, “Based on our experience
with the Probody® Platform and our clinical experience with
Probody-ADCs, we have designed CX-2051 to mask target binding in
normal tissues and include a next-generation topoisomerase-1
inhibitor payload. We are encouraged by the compelling preclinical
profile of CX-2051 and anticipate filing an IND for the program by
the end of the year. We aim to launch Phase 1 dose escalation for
CX-2051 in solid tumors in 2024, with an initial focus in
metastatic colorectal cancer as a priority indication.”
Details for the presentation are as
follows:Presentation Title: Leveraging Conditional
Activation to Localize Antibody Drug Conjugates to the Tumor
“Clinical Lessons” TrackSession Date and Time: October 18, 2023,
12:30 pm PST
The full presentation is available at
the following link:
Leveraging Conditional Activation to
Localize Antibody Drug Conjugates to the TumorMarcia P.
Belvin, Ph.D., Senior Vice President, Chief Scientific Officer,
CytomX Therapeutics
About CytomX
TherapeuticsCytomX is a clinical-stage, oncology-focused
biopharmaceutical company focused on developing novel conditionally
activated biologics localized to the tumor microenvironment. By
pioneering a novel class of conditionally activated biologics,
powered by its Probody® technology platform, CytomX’s goal is to
transcend the limits of current cancer treatments. CytomX’s robust
and differentiated pipeline comprises therapeutic candidates across
multiple treatment modalities including antibody-drug conjugates
(“ADCs”), T-cell engaging bispecific antibodies, and immune
modulators such as cytokines and checkpoint inhibitors. CX-2029 is
an investigational conditionally activated ADC directed toward
CD71. CytomX’s clinical pipeline also includes cancer
immunotherapeutic candidates against validated targets such as the
CTLA-4-targeting Probody therapeutic BMS-986288, partnered with
Bristol Myers Squibb, and CX-904, a conditionally activated
T-cell-engaging bispecific antibody targeting the epidermal growth
factor receptor (EGFR) on tumor cells and the CD3 receptor on T
cells, partnered with Amgen. In addition, CytomX has a diverse
preclinical portfolio of wholly-owned assets including CX-801, an
interferon alpha-2b Probody cytokine that has broad potential
applicability in traditionally immuno-oncology sensitive as well as
insensitive (cold) tumors and CX-20511, a conditionally activated
ADC directed toward EpCAM, with potential applicability across
multiple EpCAM-expressing epithelial cancers. CytomX has also
established strategic collaborations with multiple leaders in
oncology, including Amgen, Astellas, Bristol Myers Squibb,
Regeneron and Moderna. For more information about CytomX and how it
is working to make conditionally activated treatments the new
standard-of-care in the fight against cancer,
visit www.cytomx.com and follow us
on LinkedIn and Twitter.
CytomX Therapeutics Forward-Looking
StatementsThis press release includes forward-looking
statements. Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors that are
difficult to predict, may be beyond our control, and may cause the
actual results, performance, or achievements to be materially
different from any future results, performance or achievements
expressed or implied in such statements, including those related to
the future potential of partnerships or collaboration agreements.
Accordingly, you should not rely on any of these forward-looking
statements, including those relating to the potential benefits,
safety and efficacy or progress of CytomX’s or any of its
collaborative partners’ product candidates, including CX-2051,
CX-2029, BMS-986288, CX-904, and CX-801, the potential benefits or
applications of CytomX’s Probody platform technology, CytomX’s
ability to develop and advance product candidates into and
successfully complete clinical trials, including the ongoing and
planned clinical trials of BMS-986288, and CX-904, the timing of
the commencement of clinical trials or initial and ongoing data
availability, and the timing of investigational new drug
applications, including for CX-801 and CX-2051, and other
development milestones. Risks and uncertainties that contribute to
the uncertain nature of the forward-looking statements include: the
unproven nature of CytomX’s novel Probody Platform technology;
CytomX’s clinical trial product candidates are in the initial
stages of clinical development and its other product candidates are
currently in preclinical development, and the process by which
preclinical and clinical development could potentially lead to an
approved product is long and subject to significant risks and
uncertainties, including the possibility that the results of
preclinical research and early clinical trials may not be
predictive of future results; the possibility that CytomX’s
clinical trials will not be successful; the possibility that
current preclinical research may not result in additional product
candidates; CytomX’s dependence on the success of CX-2029,
BMS-986288, CX-904, CX-801, and CX-2051; CytomX’s reliance on third
parties for the manufacture of the Company’s product candidates;
possible regulatory developments in the United States and foreign
countries; and the risk that we may incur higher costs than
expected for research and development or unexpected costs and
expenses. Additional applicable risks and uncertainties include
those relating to our preclinical research and development,
clinical development, and other risks identified under the heading
"Risk Factors" included in CytomX’s Quarterly Report on Form 10-Q
filed with the SEC on August 8, 2023. The forward-looking
statements contained in this press release are based on information
currently available to CytomX and speak only as of the date on
which they are made. CytomX does not undertake and specifically
disclaims any obligation to update any forward-looking statements,
whether as a result of any new information, future events, changed
circumstances or otherwise.
_______________1 Licensed from Immunogen
Probody is a U.S. registered trademark of CytomX
Therapeutics, Inc.
Investor Contact:Chris
OgdenSVP, Finance and Accountingcogden@cytomx.comDirect: (317)
767-4764
Investor and Media
Contact:Stern Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com(212) 362-1200
CytomX Therapeutics (NASDAQ:CTMX)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
CytomX Therapeutics (NASDAQ:CTMX)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024